Taken together, all these observations indicate that Etrasimod might work as a superagonist/functional antagonist of the S1PR4 receptor, and further strengthen an essential role of S1PR4 signaling in an pro-inflammatory immune context such as in IBD. This evidence concerns the gene S1PR4 and inflammatory bowel disease.